Journal of Translational Internal Medicine最新文献

{"title":"Tracing down the updates on Ebola virus surges: An update on anti-ebola therapeutic strategies.","authors":"Shiza Malik,&nbsp;Yasir Waheed","doi":"10.2478/jtim-2023-0100","DOIUrl":"https://doi.org/10.2478/jtim-2023-0100","url":null,"abstract":"<p><p>Ebola virus (EBOV) related health complications have presented a great threat to the healthcare system in the endemic regions. The outbreaks of 2013-2016 and 2018-2020 brought along a huge healthcare burden for the afected communities. Knowing the seriousness of the matter, a series of research experiments have been actively carried out to devise efective therapeutics, drugs, and vaccination protocols against the Ebola virus disease (EVD) in the past decade. The purpose of this piece of literature is to shed light on vaccination protocols being clinically evaluated for EVD. A methodological approach has been adopted to gather relevant data from the latest publications. The compiled data include the molecular mechanistic insights into Ebola infection and a brief overview of diferent vaccination strategies: inactivated and DNA vaccines, virus-like particles and replicons, reverse genetic and recombinant approaches, entry, ion, and gene expression inhibitors, and some repurposed drugs. This data will help the scientific community to get a comprehensive overview of therapeutic interventions against Ebola that could be related to modifying EBOV vaccines and designing other antiviral vaccinations. Having said that, further work in modern therapeutic design is pertinent to tackle and lessen the healthcare burden expected from such outbreaks in the future.</p>","PeriodicalId":51339,"journal":{"name":"Journal of Translational Internal Medicine","volume":"11 3","pages":"216-225"},"PeriodicalIF":4.9,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10474883/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10505526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Approach to different thrombolysis techniques and timing of thrombolysis in the management of portal vein thrombosis in cirrhotic patients.","authors":"Massimo Primignani,&nbsp;Giulia Tosetti,&nbsp;Anna Maria Ierardi","doi":"10.2478/jtim-2023-0113","DOIUrl":"https://doi.org/10.2478/jtim-2023-0113","url":null,"abstract":"<p><p>Thrombolysis is not currently recommended in cirrhotic patients with acute portal vein thrombosis (PVT) in most guidelines, because of the exceedingly limited data and the perceived high risk of bleeding adverse events. However, in the few studies including patients with cirrhosis, the rate of success was high and that of adverse events was similar in patients with or without cirrhosis. Hence, thrombolysis might be a rescue therapeutic option in patients with cirrhosis and acute, symptomatic thrombosis of the portal venous system, unresponsive to anticoagulation, provided a suitable timing is kept, less than 30 days and, if possible, less than 14 days from the acute onset of portal vein thrombosis. In this review perspective article, I discuss the several potential approaches of thrombolysis, either local or systemic, alone or combined with mechanical procedures for thrombus removal, or as a complement to Transjugular Intrahepatic Portosystemic Shunt placement, with a focus on the more suitable timing of thrombolysis. However, the very limited available data preclude from performing firm recommendations, and decision to carry out thrombolysis must take into account both the occurrence of major contraindications and the current critical clinical setting. In the next future, large high-quality multicentre studies will hopefully be able to settle more firm indications and preferable techniques.</p>","PeriodicalId":51339,"journal":{"name":"Journal of Translational Internal Medicine","volume":"11 3","pages":"198-202"},"PeriodicalIF":4.9,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10474884/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10505530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>FOSL2</i> participates in renal fibrosis <i>via SGK1</i>-mediated epithelial-mesenchymal transition of proximal tubular epithelial cells.","authors":"Naiquan Liu,&nbsp;Dongyang Li,&nbsp;Dajun Liu,&nbsp;Ying Liu,&nbsp;Jing Lei","doi":"10.2478/jtim-2023-0105","DOIUrl":"https://doi.org/10.2478/jtim-2023-0105","url":null,"abstract":"<p><strong>Background: </strong>Fos-related antigen 2 (<i>FOSL2</i>) plays a facilitative role in fibrotic disease; however, its role in renal fibrosis remains unclear. This study aimed to clarify the role and underlying mechanisms of <i>FOSL2</i> in renal fibrosis.</p><p><strong>Methods: </strong>Upregulated genes in unilateral ureteral obstruction (UUO)-injured kidneys were screened in Gene Expression Omnibus (GEO) databases, and overlapping genes were identified using Venn diagram software. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were performed for these genes. The UUO-induced mouse model and transforming growth factor-β1 (TGF-β1)-induced cell model were used for the <i>in vivo</i> and <i>in vitro</i> studies.</p><p><strong>Results: </strong>A total of 43 commonly upregulated genes were identified. GO and KEGG pathway analyses indicated that <i>FOSL2</i> may be involved in fibrosis. Furthermore, <i>FOSL2</i> was confirmed to be upregulated in UUO-injured kidneys and TGF-β1-induced cells. Knockdown of <i>FOSL2</i> ameliorated interstitial fibrosis, extracellular matrix deposition, and epithelial-mesenchymal transition <i>via</i> the downregulation of fibronectin, α-smooth muscle actin (α-SMA), collagen type I (<i>Col1a1</i> and <i>Col1a2</i>), and <i>Col5a1</i> and upregulation of <i>E-cadherin</i>. Bioinformatics analysis revealed that serum/glucocorticoid regulated kinase 1 (<i>SGK1</i>) may be regulated by <i>FOSL2</i> and involved in renal fibrosis. Further experiments confirmed that TGF-β1 enhanced <i>SGK1</i> expression and transcription, which were reversed by <i>FOSL2</i> silencing. Moreover, <i>FOSL2</i> was bound to the <i>SGK1</i> promoter, and <i>SGK1</i> overexpression reversed the effects of <i>FOSL2</i> silencing in TGF-β1-induced cells.</p><p><strong>Conclusion: </strong><i>FOSL2</i> plays an essential role in promoting renal fibrosis in an <i>SGK1</i>-dependent manner, and targeting the <i>FOSL2</i>/<i>SGK1</i> signaling axis may offer a potential strategy for the treatment of renal fibrosis.</p>","PeriodicalId":51339,"journal":{"name":"Journal of Translational Internal Medicine","volume":"11 3","pages":"294-308"},"PeriodicalIF":4.9,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10474887/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10524600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mini-dose methotrexate combined with methylprednisolone as a first-line treatment for acute graft-versus-host disease: A phase 2 trial.","authors":"Zhengli Xu,&nbsp;Xiaodong Mo,&nbsp;Yuan Kong,&nbsp;Qi Wen,&nbsp;Tingting Han,&nbsp;Meng Lyu,&nbsp;Lanping Xu,&nbsp;Yingjun Chang,&nbsp;Xiaohui Zhang,&nbsp;Xiaojun Huang,&nbsp;Yu Wang","doi":"10.2478/jtim-2023-0111","DOIUrl":"https://doi.org/10.2478/jtim-2023-0111","url":null,"abstract":"<p><strong>Background and objectives: </strong>Acute graft-versus-host disease (aGvHD) remains a major complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Methylprednisolone (MP; 1-2 mg/kg/day) remains the standard first-line therapy for aGvHD, although no response is detected in nearly one-half of the patients with aGvHD. This study aimed to investigate the feasibility of mini-dose methotrexate (MTX) combined with standard-dose MP as a front-line therapy for aGvHD.</p><p><strong>Materials and methods: </strong>A prospective Phase 2 clinical trial was performed to evaluate the safety and efficacy of 5 mg/m2 MTX combined with 1 mg/kg/day MP as the initial therapy in 31 patients with aGvHD. Moreover, the effects of MTX combined with MP were explored in a humanized xenogeneic murine model of aGvHD.</p><p><strong>Results: </strong>The overall response and complete response rate at 7 days after the initial treatment were 100% and 83%, respectively. The overall response rate on day 28 was 87%. The complete response rates for aGvHD grades I, II, and III were 100% (6/6), 82% (18/22), and 66% (2/3), respectively. Grade 3 toxicities occurred in only three patients presenting with cytopenia. Importantly, MTX and MP demonstrated synergistic effects on ameliorating aGvHD in humanized xenogeneic murine model.</p><p><strong>Conclusion: </strong>The current study suggests that mini-dose MTX combined with standard-dose MP could potentially become a novel first-line therapy for patients with aGvHD.</p>","PeriodicalId":51339,"journal":{"name":"Journal of Translational Internal Medicine","volume":"11 3","pages":"255-264"},"PeriodicalIF":4.9,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10474881/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10505528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Blood eosinophils in chronic obstructive pulmonary disease: A potential biomarker.","authors":"Yanan Cui,&nbsp;Yan Chen","doi":"10.2478/jtim-2023-0096","DOIUrl":"https://doi.org/10.2478/jtim-2023-0096","url":null,"abstract":"Chronic obstructive pulmonary disease (COPD) is a common, preventable and treatable disease that is characterized by persistent respiratory symptoms and airflow limitation.[1] The underlying cellular and molecular mechanisms of COPD are still insufficiently understood. The variable clinical characteristics and differences in response to therapy suggest that COPD may have different phenotypes. The identification of phenotypes based on biomarkers could help clinicians to establish individual treatment programs for patients with COPD.","PeriodicalId":51339,"journal":{"name":"Journal of Translational Internal Medicine","volume":"11 3","pages":"193-197"},"PeriodicalIF":4.9,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10474882/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10524597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A first case report of using chimeric antigen receptor T-cell immunotherapy to treat high-risk smoldering multiple myeloma.","authors":"Yang Liu,&nbsp;Wenbing Duan,&nbsp;Xiaojun Huang,&nbsp;Jin Lu","doi":"10.2478/jtim-2023-0097","DOIUrl":"https://doi.org/10.2478/jtim-2023-0097","url":null,"abstract":"Smoldering multiple myeloma (SMM) is now considered a heterogeneous set of diseases with different tendencies to progress to active myeloma. Several trials aimed at curing multiple myeloma (MM) in the smoldering stage through intensive treatment have reported effective control of active myeloma.[1] At the same time, Chimeric antigen receptor (CAR) T-cell immunotherapy is currently being intensively tested for treating relapsed and refractory myeloma.[2] Here, we report a patient with smoldering myeloma who elected to be treated with CAR T-cell therapy and has now achieved minimal residual disease (MRD) negativity.","PeriodicalId":51339,"journal":{"name":"Journal of Translational Internal Medicine","volume":"11 3","pages":"294-296"},"PeriodicalIF":4.9,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10474885/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10524598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Protective role of autophagy in triptolide-induced apoptosis of TM3 Leydig cells.","authors":"Xiaoyun Ye,&nbsp;Liang Chen","doi":"10.2478/jtim-2021-0051","DOIUrl":"https://doi.org/10.2478/jtim-2021-0051","url":null,"abstract":"<p><strong>Background and objectives: </strong>Triptolide (TP) is known to impair testicular development and spermatogenesis in mammals, but the mechanism of the side effects still needs to be investigated. The aim of the research is to confirm whether TP can cause autophagy in TM3 Leydig cells and the potential molecular pathway in vitro.</p><p><strong>Methods: </strong>TM3 Leydig cells are used to investigate the molecular pathway through Western blot, detection of apoptosis, transmission electron microscopy for autophagosomes and so on.</p><p><strong>Results: </strong>The data show that TP treatment resulted in the decreasing of the viability of TM3 cells due to the increased apoptosis. Treated with TP, the formation of autophagosomes, the decrease in P62, and the increase in the conversion of LC3-I to LC3-II suggested the induction of autophagy. The induction of autophagy has accompanied the activation of the mTOR/P70S6K signal pathway. The viability of the TM3 cells was further inhibited when they were co-treated with autophagy inhibitor, chloroquine (CQ).</p><p><strong>Conclusion: </strong>All these data suggest that autophagy plays a very important role in antagonizing TM3 cell apoptosis during the TP exposure.</p>","PeriodicalId":51339,"journal":{"name":"Journal of Translational Internal Medicine","volume":"11 3","pages":"265-274"},"PeriodicalIF":4.9,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10474888/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10505525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endoscopic diagnosis and treatment of superficial non-ampullary duodenal epithelial tumors: A review.","authors":"Zheng Zhao,&nbsp;Yue Jiao,&nbsp;Shuyue Yang,&nbsp;Anni Zhou,&nbsp;Guiping Zhao,&nbsp;Shuilong Guo,&nbsp;Peng Li,&nbsp;Shutian Zhang","doi":"10.2478/jtim-2023-0102","DOIUrl":"https://doi.org/10.2478/jtim-2023-0102","url":null,"abstract":"<p><p>The surface of the small bowel mucosa is covered more than any other section of the digestive canal; however, the overall prevalence of small bowel tumors of the whole gastrointestinal tract is evidently low. Owing to the improvement in endoscopic techniques, the prevalence of small bowel tumors has increased across multiple countries, which is mainly due to an increase in duodenal tumors. Superficial non-ampullary duodenal epithelial tumors (SNADETs) are defined as tumors originating from the non-ampullary region in the duodenum that share similarities and discrepancies with their gastric and colorectal counterparts in the pathogenesis and clinicopathologic characteristics. To date, white light endoscopy (WLE) remains the cornerstone of endoscopic diagnosis for SNADETs. Besides, narrow-band imaging (NBI) techniques and magnifying endoscopy (ME) have been widely used in the clinic and endorsed by multiple guidelines and consensuses for SNADETs' evaluation. Confocal laser endomicroscopy (CLE), endocytoscopy (ECS), and artificial intelligence (AI) are also up-and-coming methods, showing an exceptional value in the diagnosis of SNADETs. Similar to the endoscopic treatment for colorectal polyps, the choices for SNADETs mainly include cold snare polypectomy (CSP), endoscopic mucosal resection (EMR), endoscopic submucosal dissection (ESD), and laparoscopic endoscopic cooperative surgery (LECS). However, owing to the narrow lumen, rich vascularity, weak muscle layer, abundant Brunner's gland, and the hardship of endoscope control, the duodenum ranks as one of the most dangerous operating areas in the digestive tract. Therefore, endoscopists must anticipate the difficulties in endoscopic maneuverability, remain aware of the increased risk of complications, and then select the appropriate treatment according to the advantages and disadvantages of each method.</p>","PeriodicalId":51339,"journal":{"name":"Journal of Translational Internal Medicine","volume":"11 3","pages":"206-215"},"PeriodicalIF":4.9,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10474890/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10208196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic potential and mechanisms of sacral nerve stimulation for gastrointestinal diseases.","authors":"Ximeng Wang, Jiande Dz Chen","doi":"10.2478/jtim-2023-0086","DOIUrl":"10.2478/jtim-2023-0086","url":null,"abstract":"<p><strong>Background: </strong>The aim of this systemtic review is to introduce clinical applications (especially emerging) and potential mechanisms of sacral nerve stimulation (SNS) for treating various gastrointestinal diseases.</p><p><strong>Materials and methods: </strong>PubMed and Web of Science were searched for studies published on SNS and its clinical applications in fecal incontinence (limited to systematic review and meta-analysis of clinical studies), constipation (limited to reviews and randomized control clinical studies), irritable bowel syndrome (IBS), inflammatory bowel disease (IBD) and upper gastrointestinal motility disorders. The relevant studies were pooled, and their findings were summarized and discussed.</p><p><strong>Results: </strong>SNS is an approved method for treating fecal incontinence. Systematic review and meta-analysis demonstrated high efficacy of the SNS therapy for fecal incontinence. Increased anal sphincter pressure and improvement in rectal sensation were reported as major mechanisms involved in the SNS therapy. SNS has also been proposed for treating constipation, but the therapy has been shown ineffective. There is a lack in SNS methodological optimization and mechanistic research. A few basic and clinical studies have reported the potential of SNS for treating visceral pain in IBS. SNS seemed capable of improving mucosal barrier functions. Several case reports are available in the literature on the treatment of IBD with SNS. Several laboratory studies suggested therapeutic potential of a special method of SNS for IBD. Cholinergic anti-inflammatory mechanisms were reported. Due to a recently reported spinal afferent and vagal efferent pathway of SNS, a few preclinical studies reported the potential of SNS for upper gastrointestinal motility disorders. However, no clinical studies have been performed.</p><p><strong>Conclusions: </strong>SNS for fecal incontinence is a well-established clinical therapy. However, the current method of SNS is ineffective for treating constipation. Further methodological development and randomized clinical trials are needed to explore potential applications of SNS for IBS and IBD.</p>","PeriodicalId":51339,"journal":{"name":"Journal of Translational Internal Medicine","volume":"11 2","pages":"115-127"},"PeriodicalIF":4.9,"publicationDate":"2023-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10318922/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10180392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adrenomedullin induces cisplatin chemoresistance in ovarian cancer through reprogramming of glucose metabolism.","authors":"Lei Dou,&nbsp;Enting Lu,&nbsp;Dongli Tian,&nbsp;Fangmei Li,&nbsp;Lei Deng,&nbsp;Yi Zhang","doi":"10.2478/jtim-2023-0091","DOIUrl":"https://doi.org/10.2478/jtim-2023-0091","url":null,"abstract":"<p><strong>Background and objectives: </strong>The metabolic network of cancer cells has been reprogrammed - relying more on aerobic glycolysis to gain energy, which is an important reason for drug resistance. Expression of adrenomedullin (ADM) in ovarian cancer tissues is related to resistance to platinum-based drugs. In view of this, we intended to investigate the correlation between ADM and glucose metabolism reprogramming of tumor cells to clarify the possible mechanism of ADM-induced ovarian cancer cisplatin resistance through glucose metabolism reprogramming.</p><p><strong>Methods: </strong>Epithelial ovarian cancer (EOC) cell viability and apoptosis were determined. Different gene expression and protein levels were detected by real-time revere transcription polymerase chain reaction and western blotting. Oxygen consumption rate (OCR) and extracellular acidification rates (ECARs) were measured.</p><p><strong>Results: </strong><i>ADM</i> expression was upregulated in cisplatin-resistant EOC cells. ADM attenuated cisplatin-inhibited cell survival and cisplatin-induced apoptosis in sensitive EOC cells; knockdown of ADM enhanced cisplatin chemosensitivity of cisplatin-resistant EOC cells. ADM enhanced glycolysis in cisplatin-sensitive EOC cells; knockdown of ADM significantly inhibited glycolysis in cisplatin-resistant EOC cells. ADM significantly upregulated pyruvate kinase isozyme type M2 (PKM2) protein level, the key enzyme during glycolysis; PKM2 inhibitor significantly abolished the ADM-improved cell survival and ADM-inhibited apoptosis.</p><p><strong>Conclusion: </strong>ADM promoted proliferation and inhibited apoptosis of ovarian cancer cells through reprogramming of glucose metabolism, so as to promote cisplatin resistance. The study is expected to identify multidrug resistance markers of ovarian cancer and provide a target for the prevention and treatment of ovarian cancer, which is important for clinical translational research.</p>","PeriodicalId":51339,"journal":{"name":"Journal of Translational Internal Medicine","volume":"11 2","pages":"169-177"},"PeriodicalIF":4.9,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10318923/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9803398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}